ClinicalTrials.gov
public full text
Public Domain
Relative Bioavailability Study of Marketed and Lower Dose Ambrisentan in Healthy Adult Participants
Conceptio Open Archive
Analyze & explore related research in Conceptio
Connect this record directly into your research workflow or AI agent. Explore citations across open repositories, query full text, and export structured proof bundles.
This document is indexed with metadata only: full text is not available in the archive for this record. Open the official source ↗
Related documents
- Modulation of ET1/NF-κB/IL-6/STAT-4/AP-1 pathway by ambrisentan alleviates isoprenaline-induced myocardial injury#208535
- Fed Study of Olmesartan Medoxomil and Hydrochlorothiazide Tablets 40 mg/25 mg and Benicar HCT® Tablets 40 mg/25 mg#899747
- A Study of Micro Dose Ambrisentan in Hospitalized Patients With Respiratory Insufficiency Due to COVID-19#268098
- Demographics, Diagnosis, Management, and Outcomes of Non-occlusive Mesenteric Ischemia.#1153129
- Topically Applied AMTX-100 CF for Adult Patients With Mild to Moderate Atopic Dermatitis#1007413
Record · ID 441991
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Bring this data into your agent: Connect via MCP or API · 20 free credits to start · no card required
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive